Hepatitis B is a global pandemic, being one of the rare infectious causes of the rising number of deaths globally, whereas these numbers are on the decline with all other major infections like malaria, tuberculosis, and HIV/AIDS, to name a few. We have useful antivirals against the hepatitis B virus (HBV) that can contain the disease, but we are still far away from the Holy Grail that will cure the disease once and forever. Having said so, this also has to be kept in mind that both the World Health Organization and the Sustainable Development Goal call for the effective elimination of this menace by 2030, which is a few years from now. The race is therefore on for developing the right cure for hepatitis B, and a therapeutic vaccine is one such candidate in the growing list of potential future cures for the virus. Here we discuss NASVAC, an immune-therapy for chronic hepatitis B, which is established as safe and efficacious against the virus and may well be the option that we are so eagerly looking forward to for achieving functional cure of hepatitis B to benefit the missing millions.